Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.
CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.
The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.
There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.
Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.
Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
RBC Capital Markets biotech analyst Michael Yee takes a swivel-headed approach to fundamental research.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
The Lexington, Mass.-based biotech company said Tuesday that an experimental treatment for glaucoma failed to fully demonstrate superiority over placebo in a phase III clinical trial.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Acadia Pharmaceuticals uses scant, mediocre clinical data to justify moving Nuplazid into a late-stage clinical trial of Alzheimer's disease psychosis.
Akebia's vadadustat is designed to stimulate the production of red blood cells (and the oxygen-carrying molecule hemoglobin) by mimicking the body's reaction to high altitudes.
Biogen promoted its current Chief Commercial Officer Michel Vounatsos to become the biotech company's next CEO.
Clovis will market the new drug under the brand name Rubraca.
The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.
The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.
Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.
By acquiring Claris, Baxter expects to launch seven to nine new generic injectable medicines each year over the next several years.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.